Clinical Trial Update: A Clinical Trial to Investigate Long-term Safety, Tolerability, and Efficacy of Weekly Subcutaneous Doses With TransCon CNP in Children and Adolescents With Achondroplasia [Phase 2, Phase 3]

View source ↗

Summary

This entry notes an ongoing Phase 2/Phase 3 study of TransCon CNP for Achondroplasia in children and adolescents. It is assessing long-term safety, tolerability…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Achondroplasia

Drugs mentioned

• TransCon CNP (C-type natriuretic peptide prodrug)

Snippet

Sponsor: Ascendis Pharma Growth Disorders A/S | Conditions: Achondroplasia | Phase 2, Phase 3 | Status: ENROLLING_BY_INVITATION